Document is current
Any future updates will be listed below
-
Authors
Burlando, Martina https://orcid.org/0000-0002-4381-6718
Salvi, Ilaria https://orcid.org/0000-0003-0151-3126
Parodi, Aurora
Cozzani, Emanuele
-
Funding
Funding for this research was provided by:
Almirall
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 5 August 2024
First Online: 27 August 2024
Declarations
:
: M. Burlando, A. Parodi and E. Cozzani acted as speaker and consultant for Abbvie, Janssen, Amgen, Novartis, Eli Lilly, UCB Pharma. I. Salvi has no conflicting interests.
: All subjects provided informed written consent prior to enrollment in the study. All procedures performed were in accordance with the 1964 Helsinki Declaration and its later amendments. The present study was approved by the ethics committee of Ospedale Policlinico San Martino-IRCCS, Genova, Italy (study number 163/2023; protocol: Pubb_Pso_Burlando; Study ID: 10529). All subjects gave consent to participate. Participants gave consent to the publication of anonymous data.
